Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. [clinicaltrials:NCT00145652]
Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. [clinicaltrials:NCT00145652]
Bio2RDF identifier
NCT00145652
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00145652
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This is a multi-center ...... be no longer than 18 months.
brief title [clinicaltrials_vocabulary:brief-title]
Adjuvant I.V. Iron Therapy Dur ...... Lymphoproliferative Disorders.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
completion date [clinicaltrials_vocabulary:completion-date]
2005-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
In this multi-center, r ...... n level falls below 500 ug/L.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2005-09-01T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
adjuvant iron therapy
erythropoetin
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2007-07-27T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00145652
official title [clinicaltrials_vocabulary:official-title]
Phase 3 Study of Recombinant E ...... Lymphoproliferative Disorders
org study id [clinicaltrials_vocabulary:org-study-id]
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
secondary id [clinicaltrials_vocabulary:secondary-id]
Medical Products Agency
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
2003-12-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2006-09-01T00:00:00Z
identifier
clinicaltrials:NCT00145652
title
Adjuvant I.V. Iron Therapy Dur ...... Lymphoproliferative Disorders.
@en
type
label
Adjuvant I.V. Iron Therapy Dur ...... . [clinicaltrials:NCT00145652]
@en